BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 33879104)

  • 1. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
    BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
    Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
    Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
    Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
    Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
    Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
    Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and prognosis of non-metastatic triple negative breast cancer (TNBC) among different races in Southeast Asia.
    Alcantara VS; Lim GH; Lim SH; Sultana R; Lee JA
    J Surg Oncol; 2017 Apr; 115(5):523-537. PubMed ID: 28168712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer.
    Wang H; Zhan W; Chen W; Li Y; Chen X; Shen K
    Breast; 2020 Feb; 49():33-40. PubMed ID: 31677531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
    Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcellular expression of MTA1, HIF1A and p53 in primary tumor predicts aggressive triple negative breast cancers: a meta-analysis based study.
    Sharaf SS; Jaganath Krishna KM; Lekshmi A; Sujathan
    J Mol Histol; 2024 Jun; 55(3):303-315. PubMed ID: 38613589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
    Wu W; Wu M; Peng G; Shi D; Zhang J
    Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer.
    He M; Zhang JX; Jiang YZ; Chen YL; Yang HY; Tang LC; Shao ZM; Di GH
    Oncotarget; 2017 Jul; 8(27):44870-44880. PubMed ID: 28496004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
    Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
    World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer.
    Chung SY; Jung YY; Park IA; Kim H; Chung YR; Kim JY; Park SY; Im SA; Lee KH; Moon HG; Noh DY; Han W; Lee C; Kim TY; Ryu HS
    Clin Exp Metastasis; 2016 Feb; 33(2):179-85. PubMed ID: 26585892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5.
    D'Esposito V; Liguoro D; Ambrosio MR; Collina F; Cantile M; Spinelli R; Raciti GA; Miele C; Valentino R; Campiglia P; De Laurentiis M; Di Bonito M; Botti G; Franco R; Beguinot F; Formisano P
    Oncotarget; 2016 Apr; 7(17):24495-509. PubMed ID: 27027351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
    Mitra D; Bhattacharyya S; Alam N; Sen S; Mitra S; Mandal S; Vignesh S; Majumder B; Murmu N
    Breast Cancer Res Treat; 2020 Jan; 179(2):359-370. PubMed ID: 31686261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-bet
    Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
    Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.